Results for this period
First quarter21 January 2026 to 20 April 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Net sales benefited from strong performance in the overseas beverages business, led by the Turkish beverages business. Operating profit benefited from lower depreciation and amortization expenses and improved profitability in the domestic beverages business, as well as increased profitability in the overseas beverages business.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 21 January 2026 to 20 April 2026 |
| Net Sales | ¥55,239 million (YoY +4.3%) |
| Operating profit | ¥1,556 million |
| Ordinary income | ¥459 million |
| Profit attributable to owners of the parent | ¥110 million |
| Net income per share | ¥3.49 |
| Equity ratio | End of the current fiscal period 41.6 / End of previous period 39.5 |
| Total assets | ¥157,465 million |
| Net assets | ¥65,995 million |
| Full-year earnings forecast | Net Sales ¥246,800 million (YoY +2.3%) / Operating profit ¥10,500 million (YoY +152.2%) / Ordinary income ¥8,400 million (YoY +472.5%) / Net income ¥5,000 million |
| Annual Dividend Forecast | ¥30 → ¥30（0.0%） |
| Segment revenue | Domestic Beverage Business ¥31,731 million (YoY -2.0%), Overseas beverage business ¥16,505 million (YoY +28.0%), Pharmaceutical-Related Businesses ¥2,974 million (YoY -11.5%), Food Business ¥3,846 million (YoY -10.1%), Orphan-drug business ¥228 million (YoY +62.8%) |
| Segment profit | Domestic Beverage Business ¥-185 million, Overseas beverage business ¥2,291 million (YoY +135.6%), Pharmaceutical-Related Businesses ¥54 million (YoY -66.5%), Food Business ¥-167 million, Orphan-drug business ¥-40 million |
| Depreciation and amortization | ¥1,371 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | 0 additions (company name: —), 0 exclusions (company name: —) |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | None (対象者：Not disclosed) |
| Issued Shares at Period-End | 33,137,000 |
| Treasury Shares at Period-End | 1,438,163 |
| Factors Behind Changes in Business Performance | Net sales benefited from strong performance in the overseas beverages business, led by the Turkish beverages business. Operating profit benefited from lower depreciation and amortization expenses and improved profitability in the domestic beverages business, as well as increased profitability in the overseas beverages business. |
Items this document does not state (13)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the domestic beverages business, lower depreciation and amortization expenses following the impairment loss recognized in the previous consolidated fiscal year, together with improved profitability, contributed to the improvement in profit. In the overseas beverages business, increased profitability also contributed. Net sales benefited from strong performance in the overseas beverages business, led by the Turkish beverages business.